Figure 3 | Scientific Reports

Figure 3

From: High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy

Figure 3

Clinical timeline for patient S-26. The timeline extends from January 2013 (first diagnosis) to March 2017 (last recorded checkup). Lines of treatment, tissue and liquid biopsies, and corresponding results of ESR1 Y537S mutation analyses (after a regular droplet digital PCR [ddPCR] or after enhanced-ice-COLD-PCR [E-COLD]) are displayed. The percentages of mutations in tissues (primary and metastasis) were assessed by next-generation sequencing and ddPCR analyses. EC: Epirubicin/Cyclophosphamide; VC: Vinorelbine/Capecitabine; P + L: Palbociclib + Letrozole

Back to article page